MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

Abstract Background Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm whose pathogenesis is linked to the Philadelphia chromosome presence that generates the BCR–ABL1 fusion oncogene. Tyrosine kinase inhibitors (TKI) such as imatinib mesylate (IM) dramatically improved the treat...

Full description

Bibliographic Details
Main Authors: Doralina do Amaral Rabello, Vivian D’Afonseca da Silva Ferreira, Maria Gabriela Berzoti-Coelho, Sandra Mara Burin, Cíntia Leticia Magro, Maira da Costa Cacemiro, Belinda Pinto Simões, Felipe Saldanha-Araujo, Fabíola Attié de Castro, Fabio Pittella-Silva
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Cancer Cell International
Subjects:
MLL2/KMT2D
MLL3/KMT2C
Chronic myeloid leukemia
Genetic alterations
Epigenetic
Lysine methyltransferase
Online Access:http://link.springer.com/article/10.1186/s12935-018-0523-1

Internet

http://link.springer.com/article/10.1186/s12935-018-0523-1

Similar Items